Long-term Future Risk of Severe Exacerbations: Distinct 5-year Trajectories of Problematic Asthma
Overview
Authors
Affiliations
Background: Assessing future risk of exacerbations is an important component of asthma management. Existing studies have investigated short- but not long-term risk. Problematic asthma patients with unfavorable long-term disease trajectory and persistently frequent severe exacerbations need to be identified early to guide treatment.
Aim: To identify distinct trajectories of severe exacerbation rates among "problematic asthma" patients and develop a risk score to predict the most unfavorable trajectory.
Methods: Severe exacerbation rates over five years for 177 "problematic asthma" patients presenting to a specialist asthma clinic were tracked. Distinct trajectories of severe exacerbation rates were identified using group-based trajectory modeling. Baseline predictors of trajectory were identified and used to develop a clinical risk score for predicting the most unfavorable trajectory.
Results: Three distinct trajectories were found: 58.5% had rare intermittent severe exacerbations ("infrequent"), 32.0% had frequent severe exacerbations at baseline but improved subsequently ("nonpersistently frequent"), and 9.5% exhibited persistently frequent severe exacerbations, with the highest incidence of near-fatal asthma ("persistently frequent"). A clinical risk score composed of ≥2 severe exacerbations in the past year (+2 points), history of near-fatal asthma (+1 point), body mass index ≥25kg/m (+1 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point), and depression (+1 point) was predictive of the "persistently frequent" trajectory (area under the receiver operating characteristic curve: 0.84, sensitivity 72.2%, specificity 81.1% using cutoff ≥3 points). The trajectories and clinical risk score had excellent performance in an independent validation cohort.
Conclusions: Patients with problematic asthma follow distinct illness trajectories over a period of five years. We have derived and validated a clinical risk score that accurately identifies patients who will have persistently frequent severe exacerbations in the future.
Paggiaro P, Garcia G, Roche N, Verma M, Plank M, Oosterholt S Adv Ther. 2024; 41(11):4065-4088.
PMID: 39240503 PMC: 11480127. DOI: 10.1007/s12325-024-02962-2.
Tiew P, Tay T, Chen W, Price D, Ong K, Chotirmall S J Allergy Clin Immunol Glob. 2024; 3(1):100188.
PMID: 38173699 PMC: 10762473. DOI: 10.1016/j.jacig.2023.100188.
Revisiting Asthma Obstructive Sleep Apnea Overlap: Current Knowledge and Future Needs.
Saxena D, Imayama I, Adrish M J Clin Med. 2023; 12(20).
PMID: 37892689 PMC: 10607310. DOI: 10.3390/jcm12206552.
Yii A, Xu X, Loh C, Bahety P, Navarro Rojas A, Milea D BMJ Open. 2023; 13(9):e072571.
PMID: 37657841 PMC: 10476133. DOI: 10.1136/bmjopen-2023-072571.
Severe asthma trajectories in adults: findings from the NORDSTAR cohort.
von Bulow A, Hansen S, Sandin P, Ernstsson O, Janson C, Lehtimaki L Eur Respir J. 2023; 62(3).
PMID: 37620041 PMC: 10492664. DOI: 10.1183/13993003.02474-2022.